Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.150
Open
1.120
VWAP
1.11
Vol
344.59K
Mkt Cap
25.86M
Low
1.100
Amount
383.56K
EV/EBITDA(TTM)
--
Total Shares
8.62M
EV
-22.98M
EV/OCF(TTM)
--
P/S(TTM)
49.66
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
0.00
-100%
-0.110
-76.09%
--
--
-0.080
-83.33%
--
--
-0.080
-83.67%
Estimates Revision
The market is revising Downward the revenue expectations for iBio, Inc. (IBIO) for FY2026, with the revenue forecasts being adjusted by -68.75% over the past three months. During the same period, the stock price has changed by 68.14%.
Revenue Estimates for FY2026
Revise Downward
-68.75%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
-65.35%
In Past 3 Month
Stock Price
Go Up
+68.14%
In Past 3 Month
3 Analyst Rating
Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 3.20 USD with a low forecast of 1.60 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.140
Low
1.60
Averages
3.20
High
6.00
Current: 1.140
Low
1.60
Averages
3.20
High
6.00
Oppenheimer
Jay Olson
Outperform
maintain
$5 -> $6
2025-10-30
Reason
Oppenheimer
Jay Olson
Price Target
$5 -> $6
2025-10-30
maintain
Outperform
Reason
Oppenheimer analyst Jay Olson raised the firm's price target on iBio to $6 from $5 and keeps an Outperform rating on the shares. The firm notes shares were up 8% vs. flat XBI, basking in well-deserved attention for IBIO-610 following updates from WVE's INHBE-targeting siRNA WVE-007. In its Phase 1 INLIGHT trial, WVE-007 elicited up to about 85% activin E reduction, surpassing the preclinical 70% activin E reduction threshold for potential 6-month weight loss comparable to semaglutide.
Oppenheimer
Oppenheimer
Outperform
maintain
$5 -> $6
2025-10-29
Reason
Oppenheimer
Oppenheimer
Price Target
$5 -> $6
2025-10-29
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on iBio (IBIO) to $6 from $5 and keeps an Outperform rating on the shares, calling attention for IBIO-610 following updates from Wave Life Sciences' (WVE) WVE-007 "well-deserved." Wave's initial Phase 1 INLIGHT efficacy and safety readout this quarter could provide mechanistic validation for iBio's '601 and drive additional upside, the analyst tells investors.
Oppenheimer
Outperform
initiated
$5
2025-10-20
Reason
Oppenheimer
Price Target
$5
2025-10-20
initiated
Outperform
Reason
Oppenheimer initiated coverage of iBio with an Outperform rating and $5 price target, citing "optimism" for lead asset IBIO-610 to address key challenges in treating the growing obesity market. Preclinical data validate the potential of '610 to drive both fat loss and lean mass preservation, supporting "a highly differentiated and complementary profile," says the analyst, who views the drug as "an under-the-radar" next-generations approach that "could command strategic interest."
Leerink
Roanna Ruiz
Outperform
initiated
$2
2025-10-17
Reason
Leerink
Roanna Ruiz
Price Target
$2
2025-10-17
initiated
Outperform
Reason
Leerink analyst Roanna Ruiz initiated coverage of iBio with an Outperform rating and $2 price target. The firm argues that lead obesity asset IBIO-610 represents a preclinically validated, first-in-class antibody opportunity that could address the safety and durability limitations of RNA-based competitors. Following the recent $50M public offering, iBio should maintain liquidity through all pre-IND and IND catalysts, with Series G and H warrants providing up to an additional $50M in contingent capital tied to IND milestones, Leerink adds. This structure should support a self-funding runway through the second half of 2026, aligning with the expected IND filings for IBIO-610 and IBIO-600 by year-end 2026. Further, the firm believes iBio's proprietary AI/ML-driven antibody discovery and engineering platform should provide enhanced scalability and speed to identify and optimize novel biologics.
LUCID CAPITAL MARKETS
Dev Prasad
Strong Buy
Initiates
$6
2024-12-17
Reason
LUCID CAPITAL MARKETS
Dev Prasad
Price Target
$6
2024-12-17
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for iBio Inc (IBIO.A) is -2.84, compared to its 5-year average forward P/E of -4.17. For a more detailed relative valuation and DCF analysis to assess iBio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.17
Current PE
-2.84
Overvalued PE
3.18
Undervalued PE
-11.52
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
74.24
Current PS
1.15
Overvalued PS
170.22
Undervalued PS
-21.73
Financials
Annual
Quarterly
FY2026Q1
100.00K
Total Revenue
FY2026Q1
YoY :
+44.93%
-5.95M
Operating Profit
FY2026Q1
YoY :
-100.00%
N/A
Net Income after Tax
FY2026Q1
YoY :
-76.09%
-0.11
EPS - Diluted
FY2026Q1
YoY :
+53.35%
-5.70M
Free Cash Flow
FY2026Q1
N/A
Gross Profit Margin - %
FY2026Q1
YoY :
-64.67%
-3.46K
FCF Margin - %
FY2026Q1
-5.72K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
7
655.0K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
7
655.0K
USD
Months
IBIO News & Events
Events Timeline
2025-11-12 (ET)
2025-11-12
16:14:33
iBio Announces Q1 Earnings Per Share of 11 Cents, Exceeding Consensus Estimate of 7 Cents
2025-10-30 (ET)
2025-10-30
07:15:52
iBio Reveals New Preclinical Findings from NHP Study of IBIO-1610
2025-09-05 (ET)
2025-09-05
07:31:36
iBio Announces FY25 EPS of $1.75 Compared to ($6.50) in the Previous Year
Sign Up For More Events
Sign Up For More Events
News
9.0
10-30NewsfilteriBio Reveals Promising Non-Human Primate Data for IBIO-610, an Activin E Antibody with Significant Potential for Targeted Weight Loss and Maintenance
1.0
10-23NewsfilteriBio to Attend the 2nd Annual Healthcare Innovation Conference Hosted by Guggenheim
9.0
10-23NASDAQ.COMVTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Sign Up For More News
People Also Watch
MRKR
Marker Therapeutics Inc
0.900
USD
+0.90%
CTRM
Castor Maritime Inc
1.930
USD
0.00%
CREX
Creative Realities Inc
2.660
USD
0.00%
HYFM
Hydrofarm Holdings Group Inc
1.820
USD
0.00%
IPW
iPower Inc
9.650
USD
+0.05%
PZG
Paramount Gold Nevada Corp
1.135
USD
+5.09%
NXGL
Nexgel Inc
1.900
USD
0.00%
CPSH
CPS Technologies Corp
3.350
USD
-1.47%
IGC
IGC Pharma Inc
0.357
USD
+0.28%
FAQ
What is iBio Inc (IBIO) stock price today?
The current price of IBIO is 1.14 USD — it has decreased -0.87 % in the last trading day.
What is iBio Inc (IBIO)'s business?
What is the price predicton of IBIO Stock?
What is iBio Inc (IBIO)'s revenue for the last quarter?
What is iBio Inc (IBIO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for iBio Inc (IBIO)'s fundamentals?
How many employees does iBio Inc (IBIO). have?